TOKYO and CAMBRIDGE, Mass., Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril(1) antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s […]
NEW YORK, NY, Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – PCG Digital — Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, is on track to deliver a safe and effective front-line treatment to a community of patients living with a rare, chronic cancer. [Image: Soligenix, Inc.] Cutaneous T-cell lymphoma (CTCL) is difficult to […]
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 17, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in […]
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 16, 2022 – (ACN Newswire via SEAPRWire.com) – HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in […]
HONG KONG, Oct 28, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or “the Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacturing and commercialization of treatments that address significant unmet medical needs, is pleased to announce that the Company’s partner Vyluma, Inc. (“Vyluma”) , a […]
MANILA, Sep 27, 2022 – (ACN Newswire via SEAPRWire.com) – BPipe Corporation, an equity joint venture partner of Biopipe Global USA, enters into an agreement with a major global food company to install a 10 m3/day Biopipe biological sewage wastewater treatment plant. BPipe Corporation is focused on innovative, scalable and disruptive decentralized wastewater treatment and […]
HONG KONG, Sep 15, 2022 – (ACN Newswire via SEAPRWire.com) – Analogue Holdings Limited (stock code: 1977) together with its subsidiaries (referred to as “ATAL Engineering Group”, “ATAL” or the “Group”), a leading electrical and mechanical (“E&M”) engineering services provider in Hong Kong, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted […]
HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 23 […]
LAUSANNE, Switzerland, Aug 23, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (‘Oculis’) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the results of the double blinded, multicenter and placebo controlled Phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on […]
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient received their first dose on July 29, 2022. The bridging study is a multicenter, open-label, Phase II […]
–6th Orphan Drug Designation granted to toripalimab in the US and EU SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that toripalimab, a PD-1 inhibitor […]